
eph-15,599

enlx-101 ennum ariyappedunna eph-15,599, shakthavum selective 5-echti1eiii risapttar phul agonistaanu. raafi nucleusile somatodendritic autoriseptarukalil kaaryamaaya swaadheenam cheluthaathe poost synaptic prefrondal courtexil 5-echu. tii. 1eiii resepterukal shakthamayi sajeevamaakkunnathiloode ithu pravarthanaparamaaya selectivity ("biased agonism" ennum ariyappedunnu) pradarshippikkunnu. thalphalamaayi, ithu oru munganana poost synaptic 5-echu. tii. 1eiii risapttar agonistaayi visheshippikkappedukayum oru puthiya pottensial aantidiprasantaayi anweshikkappedukayum cheythu.
elikalil nadatthiya vaijnjaanika parisodhanakalil, eph-15,599 enmdi risapttar aantagonist pcp kandethiya memory kammi kuraykkunnu, ithu schisophrenia polulla vaikalyangalil vaijnjaanika pravartthanam mechappeduthumennu soochippikkunnu.
thudarnnulla oru patanam kaanikkunnath eph-15,599 shwasana kramakkedum messipi 2 jeeninte mutationukalulla elikalil kaanapedunna apnia kuraykkunnu ennaanu. messipi2 jeane expression thakaraarilaakunnath neuro developmental anatha rogamaaya rettu syndrome aanu.
franch farmaceuticals kambaniyaaya piyari fabrey medicament aanu eph-15,599 kandethukayum aadyam vikasippikkukayum cheythath. 2013 septambaril eph-15,599 california aasthaanamaayulla biotechnology kambaniyaaya neurolixisinu licenses nalki. rettu syndrome chikilsaykkaayi eph-15,599 veendum upayogikkaan uddeshikkunnathaayi neurolixis prakhyaapichu. eee soochanaykkaayi yunaittad stetts phudu aandu drugg administrationil (fda) ninnum europian commissionil ninnum anatha mayakkumarunnu padavi nedi.
internaashanal rettu syndrome foundeshante pinthunayode rettu syndrome mrugangalude modalukalil eph-15599-nte pravartthanam bristtol sarvakalaashaalayile gaveshakar anweshikkunnu. 2015 juunil, rettu syndrome research trastt eph-15599 klinikkal vikasanathilekku munnerunnathinaayi neurolixisinu oru graant nalki.

